| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802977301016 | 297730101 | VALSABEN F.C.TAB 80MG/TAB BTx28 | 3.21 | 3.37 | 4.64 |
| 05/2018 | 2802977301030 | 297730103 | VALSABEN F.C.TAB 80MG/TAB BTx14 | 02.05 | 2.15 | 2.97 |
| 05/2018 | 2802977302013 | 297730201 | VALSABEN F.C.TAB 160MG/TAB BTx28 | 3.98 | 4.18 | 5.76 |
| 05/2018 | 2802977302037 | 297730203 | VALSABEN F.C.TAB 160MG/TAB BTx14 | 2.28 | 2.39 | 3.30 |
| 05/2018 | 2802977303010 | 297730301 | VALSABEN F.C.TAB 320MG/TAB BTx28 | 6.23 | 6.53 | 9.00 |
| 05/2018 | 2802977303034 | 297730303 | VALSABEN F.C.TAB 320MG/TAB BTx14 | 3.54 | 3.71 | 5.11 |
| 05/2018 | 2802979301014 | 297930101 | VALSABEN PLUS F.C.TAB (80+12,5)MG/TAB BTx30 | 3.78 | 3.97 | 5.47 |
| 05/2018 | 2802979301021 | 297930102 | VALSABEN PLUS F.C.TAB (80+12,5)MG/TAB BTx14 | 2.23 | 2.34 | 3.22 |
| 05/2018 | 2802979302011 | 297930201 | VALSABEN PLUS F.C.TAB (160+12,5)MG/TAB BTx30 | 5.14 | 5.39 | 7.43 |
| 05/2018 | 2802979302028 | 297930202 | VALSABEN PLUS F.C.TAB (160+12,5)MG/TAB BTx14 | 3.15 | 3.30 | 4.55 |
| 05/2018 | 2802979303018 | 297930301 | VALSABEN PLUS F.C.TAB (160+25)MG/TAB BTx30 | 4.67 | 4.90 | 6.75 |
| 05/2018 | 2802979303025 | 297930302 | VALSABEN PLUS F.C.TAB (160+25)MG/TAB BTx14 | 2.59 | 2.72 | 3.75 |
| 05/2018 | 2802979304015 | 297930401 | VALSABEN PLUS F.C.TAB (320+12,5)MG/TAB BTx30 | 8.28 | 8.69 | 11.98 |
| 05/2018 | 2802979304022 | 297930402 | VALSABEN PLUS F.C.TAB (320+12,5)MG/TAB BTx14 | 5.21 | 5.47 | 7.54 |
| 05/2018 | 2802979305012 | 297930501 | VALSABEN PLUS F.C.TAB (320+25)MG/TAB BTx30 | 8.94 | 9.38 | 12.92 |
| 05/2018 | 2802979305029 | 297930502 | VALSABEN PLUS F.C.TAB (320+25)MG/TAB BTx14 | 5.36 | 5.62 | 7.75 |
For the treatment of hypertension.
Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Absolute bioavailability = 23% with high variability
The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
* 17 L
* 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]